LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.
<h4>Background</h4>Options are limited for patients with atopic dermatitis (AD) who do not respond to topical treatments. Antifolate therapy with systemic methotrexate improves the disease, but is associated with adverse effects. The investigational antifolate LD-aminopterin may offer im...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0108303&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171817673621504 |
|---|---|
| author | John A Zebala Alan Mundell Linda Messinger Craig E Griffin Aaron D Schuler Stuart J Kahn |
| author_facet | John A Zebala Alan Mundell Linda Messinger Craig E Griffin Aaron D Schuler Stuart J Kahn |
| author_sort | John A Zebala |
| collection | DOAJ |
| description | <h4>Background</h4>Options are limited for patients with atopic dermatitis (AD) who do not respond to topical treatments. Antifolate therapy with systemic methotrexate improves the disease, but is associated with adverse effects. The investigational antifolate LD-aminopterin may offer improved safety. It is not known how antifolate dose and dosing frequency affect efficacy in AD, but a primary mechanism is thought to involve the antifolate-mediated accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). However, recent in vitro studies indicate that AICAR increases then decreases as a function of antifolate concentration. To address this issue and understand how dosing affects antifolate efficacy in AD, we examined the efficacy and safety of different oral doses and schedules of LD-aminopterin in the canine model of AD.<h4>Methods and findings</h4>This was a multi-center, double-blind trial involving 75 subjects with canine AD randomized to receive up to 12 weeks of placebo, once-weekly (0.007, 0.014, 0.021 mg/kg) or twice-weekly (0.007 mg/kg) LD-aminopterin. The primary efficacy outcome was the Global Score (GS), a composite of validated measures of disease severity and itch. GS improved in all once-weekly cohorts, with 0.014 mg/kg being optimal and significant (43%, P<0.01). The majority of improvement was seen by 8 weeks. In contrast, GS in the twice-weekly cohort was similar to placebo and worse than all once-weekly cohorts. Adverse events were similar across all treated cohorts and placebo.<h4>Conclusions</h4>Once-weekly LD-aminopterin was safe and efficacious in canine AD. Twice-weekly dosing negated efficacy despite having the same daily and weekly dose as effective once-weekly regimens. Optimal dosing in this homologue of human AD correlated with the concentration-selective accumulation of AICAR in vitro, consistent with AICAR mediating LD-aminopterin efficacy in AD. |
| format | Article |
| id | doaj-art-c63a1564e21748128ffa4150fefdaa12 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c63a1564e21748128ffa4150fefdaa122025-08-20T02:20:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10830310.1371/journal.pone.0108303LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.John A ZebalaAlan MundellLinda MessingerCraig E GriffinAaron D SchulerStuart J Kahn<h4>Background</h4>Options are limited for patients with atopic dermatitis (AD) who do not respond to topical treatments. Antifolate therapy with systemic methotrexate improves the disease, but is associated with adverse effects. The investigational antifolate LD-aminopterin may offer improved safety. It is not known how antifolate dose and dosing frequency affect efficacy in AD, but a primary mechanism is thought to involve the antifolate-mediated accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). However, recent in vitro studies indicate that AICAR increases then decreases as a function of antifolate concentration. To address this issue and understand how dosing affects antifolate efficacy in AD, we examined the efficacy and safety of different oral doses and schedules of LD-aminopterin in the canine model of AD.<h4>Methods and findings</h4>This was a multi-center, double-blind trial involving 75 subjects with canine AD randomized to receive up to 12 weeks of placebo, once-weekly (0.007, 0.014, 0.021 mg/kg) or twice-weekly (0.007 mg/kg) LD-aminopterin. The primary efficacy outcome was the Global Score (GS), a composite of validated measures of disease severity and itch. GS improved in all once-weekly cohorts, with 0.014 mg/kg being optimal and significant (43%, P<0.01). The majority of improvement was seen by 8 weeks. In contrast, GS in the twice-weekly cohort was similar to placebo and worse than all once-weekly cohorts. Adverse events were similar across all treated cohorts and placebo.<h4>Conclusions</h4>Once-weekly LD-aminopterin was safe and efficacious in canine AD. Twice-weekly dosing negated efficacy despite having the same daily and weekly dose as effective once-weekly regimens. Optimal dosing in this homologue of human AD correlated with the concentration-selective accumulation of AICAR in vitro, consistent with AICAR mediating LD-aminopterin efficacy in AD.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0108303&type=printable |
| spellingShingle | John A Zebala Alan Mundell Linda Messinger Craig E Griffin Aaron D Schuler Stuart J Kahn LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. PLoS ONE |
| title | LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. |
| title_full | LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. |
| title_fullStr | LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. |
| title_full_unstemmed | LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. |
| title_short | LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. |
| title_sort | ld aminopterin in the canine homologue of human atopic dermatitis a randomized controlled trial reveals dosing factors affecting optimal therapy |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0108303&type=printable |
| work_keys_str_mv | AT johnazebala ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy AT alanmundell ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy AT lindamessinger ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy AT craigegriffin ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy AT aarondschuler ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy AT stuartjkahn ldaminopterininthecaninehomologueofhumanatopicdermatitisarandomizedcontrolledtrialrevealsdosingfactorsaffectingoptimaltherapy |